PubRank

Roman Yelensky

Author PubWeight™ 99.67‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficiency and power in genetic association studies. Nat Genet 2005 25.56
2 Evaluating and improving power in whole-genome association studies using fixed marker sets. Nat Genet 2006 14.76
3 Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet Epidemiol 2008 11.28
4 Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013 7.97
5 Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012 6.77
6 Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet 2008 5.08
7 Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet 2006 4.78
8 Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2012 2.39
9 The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A 2009 2.38
10 D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 2013 2.05
11 Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol 2013 1.71
12 New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014 1.61
13 Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther 2014 1.57
14 Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2013 1.54
15 Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 2012 1.38
16 Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget 2014 1.34
17 Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol 2013 1.16
18 Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res 2013 1.14
19 A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res 2013 1.12
20 A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Oncologist 2014 0.93
21 Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies. Am J Surg Pathol 2014 0.91
22 Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget 2013 0.89
23 Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options. Arch Pathol Lab Med 2015 0.89
24 RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab 2014 0.87
25 Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. J Natl Cancer Inst 2015 0.83
26 Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology 2016 0.75